These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 3998204

  • 1. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA, Silver MA.
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [Abstract] [Full Text] [Related]

  • 2. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U, Greenberg D, Lerer B, Javitt DC, Brown WA.
    Isr J Psychiatry Relat Sci; 1997 Jun; 34(4):281-9. PubMed ID: 9409085
    [Abstract] [Full Text] [Related]

  • 3. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G, Coyle J, Tune L.
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [Abstract] [Full Text] [Related]

  • 4. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 5. Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome.
    Turbott J, Villiger J, Hunter L.
    Aust N Z J Psychiatry; 1987 Sep; 21(3):327-38. PubMed ID: 3435373
    [Abstract] [Full Text] [Related]

  • 6. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B.
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [Abstract] [Full Text] [Related]

  • 7. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV, Brown WA, Laughren TP.
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [Abstract] [Full Text] [Related]

  • 8. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K.
    Acta Psychiatr Belg; 1982 Apr; 82(2):216-23. PubMed ID: 7180558
    [Abstract] [Full Text] [Related]

  • 9. Fluphenazine blood levels and clinical response.
    Harris PQ, Friedman MJ, Cohen BM, Cooper TB.
    Biol Psychiatry; 1982 Oct; 17(10):1123-30. PubMed ID: 7171656
    [Abstract] [Full Text] [Related]

  • 10. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D.
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [Abstract] [Full Text] [Related]

  • 11. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA, Milanes F, Starkey T, Slater V, Dominguez F.
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract] [Full Text] [Related]

  • 12. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC, Sweet RA, Chengappa KN, Reddy RR, Jeste DV.
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [Abstract] [Full Text] [Related]

  • 13. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS, Faraone SV, Brown WA.
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [Abstract] [Full Text] [Related]

  • 14. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC, Kennedy NM, Gribbon D.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [Abstract] [Full Text] [Related]

  • 15. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE, Creese I, Coyle JT, Pearlson G, Snyder SH.
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [Abstract] [Full Text] [Related]

  • 16. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E, Quadbeck H, Tegeler J, Fararuni M, Heinrich K.
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [Abstract] [Full Text] [Related]

  • 17. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [Abstract] [Full Text] [Related]

  • 18. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
    Siris SG, Adan F, Lee A, Cooper TB, Mandeli J, Casey E.
    J Clin Psychiatry; 1988 Feb; 49(2):64-5. PubMed ID: 3338977
    [Abstract] [Full Text] [Related]

  • 19. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
    Turbott J, Villiger J, Hunter L.
    Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
    [Abstract] [Full Text] [Related]

  • 20. Fluphenazine plasma levels and clinical response.
    Marder SR, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J, Midha KK.
    Psychopharmacol Bull; 1990 Apr; 26(2):256-9. PubMed ID: 2236467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.